IRIS
PISANI, ANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 6.662
EU - Europa 5.539
NA - Nord America 5.339
SA - Sud America 983
AF - Africa 215
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 6
AN - Antartide 1
Totale 18.754
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.071
SG - Singapore 3.670
RU - Federazione Russa 2.641
CN - Cina 1.428
IT - Italia 1.330
BR - Brasile 762
VN - Vietnam 581
HK - Hong Kong 553
DE - Germania 318
FI - Finlandia 214
UA - Ucraina 156
CA - Canada 146
GB - Regno Unito 146
IE - Irlanda 138
FR - Francia 119
NL - Olanda 118
IN - India 99
AR - Argentina 98
MX - Messico 87
SE - Svezia 74
CI - Costa d'Avorio 62
ZA - Sudafrica 62
PL - Polonia 58
RO - Romania 47
BD - Bangladesh 44
EC - Ecuador 41
KR - Corea 36
JP - Giappone 32
TR - Turchia 28
IQ - Iraq 26
AT - Austria 25
CO - Colombia 23
ID - Indonesia 23
ES - Italia 22
MK - Macedonia 22
BE - Belgio 17
IR - Iran 17
VE - Venezuela 16
MA - Marocco 15
EG - Egitto 13
LT - Lituania 13
PK - Pakistan 12
UZ - Uzbekistan 12
IL - Israele 11
RS - Serbia 11
TN - Tunisia 11
BG - Bulgaria 10
KE - Kenya 10
NP - Nepal 10
PE - Perù 10
UY - Uruguay 10
JO - Giordania 9
CH - Svizzera 8
CL - Cile 8
PY - Paraguay 8
ET - Etiopia 7
GR - Grecia 7
KG - Kirghizistan 7
JM - Giamaica 6
SA - Arabia Saudita 6
AE - Emirati Arabi Uniti 5
DZ - Algeria 5
KH - Cambogia 5
KZ - Kazakistan 5
MY - Malesia 5
TT - Trinidad e Tobago 5
AU - Australia 4
BO - Bolivia 4
CZ - Repubblica Ceca 4
DO - Repubblica Dominicana 4
EE - Estonia 4
EU - Europa 4
HN - Honduras 4
MN - Mongolia 4
PS - Palestinian Territory 4
PT - Portogallo 4
SI - Slovenia 4
AO - Angola 3
BB - Barbados 3
BH - Bahrain 3
BJ - Benin 3
BY - Bielorussia 3
CY - Cipro 3
DK - Danimarca 3
GE - Georgia 3
HR - Croazia 3
LV - Lettonia 3
NI - Nicaragua 3
NO - Norvegia 3
QA - Qatar 3
SK - Slovacchia (Repubblica Slovacca) 3
SY - Repubblica araba siriana 3
AM - Armenia 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
CU - Cuba 2
CW - ???statistics.table.value.countryCode.CW??? 2
GH - Ghana 2
GT - Guatemala 2
GY - Guiana 2
Totale 18.699
Salva come PNG Salva come JPEG
Città #
Singapore 1.603
Moscow 659
Hong Kong 552
Chandler 547
Beijing 482
Ashburn 442
Santa Clara 306
Hefei 230
Napoli 223
Millbury 215
Los Angeles 184
Ho Chi Minh City 172
Naples 170
Princeton 154
Nanjing 145
Dong Ket 142
Boston 137
Jacksonville 119
Des Moines 98
Wilmington 94
Buffalo 90
Munich 87
New York 84
Amsterdam 79
Redondo Beach 79
São Paulo 79
Milan 70
Hanoi 69
Rome 69
Dublin 62
Lawrence 56
Ottawa 55
Bucharest 45
Warsaw 45
Seattle 42
Mexico City 40
Nanchang 40
Helsinki 38
Montreal 38
Dallas 35
Seoul 35
Caserta 34
Orem 34
Frankfurt am Main 33
Johannesburg 32
Nuremberg 32
Denver 31
The Dalles 31
Brooklyn 30
Shenyang 30
Houston 29
Rio de Janeiro 29
Tokyo 29
Buenos Aires 28
Hebei 28
Poplar 28
Stockholm 28
Haiphong 27
Turku 26
Chennai 24
Chicago 24
Boardman 23
London 22
Toronto 22
Falkenstein 21
Da Nang 20
Tianjin 20
Woodbridge 20
Phoenix 19
Redwood City 19
San Francisco 19
Washington 19
Atlanta 18
Norwalk 17
Augusta 16
Brasília 16
Hải Dương 15
Jiaxing 15
Manchester 15
Changsha 14
Florence 14
Querétaro 14
Vienna 14
Biên Hòa 13
Quito 13
Turin 13
Baghdad 12
Ann Arbor 11
Belo Horizonte 11
Council Bluffs 11
Courcelles 11
Düsseldorf 11
Kunming 11
Ninh Bình 11
Porto Alegre 11
Campinas 10
Guayaquil 10
Nairobi 10
Sciacca 10
Shanghai 10
Totale 9.079
Salva come PNG Salva come JPEG
Nome #
Polimirfismo del gene dell'ACE ed eritrocitosi nel trapianto di rene 422
Il nefrologo nel trattamento dell’iperammoniemia da disordini del ciclo dell’urea 204
Liposomial iron: a new proposal for the treatment of anaemia in chronic kidney disease 163
Aortopathies in mouse models of Pompe, Fabry and Mucopolysaccharidosis IIIB lysosomal storage diseases 162
Effect of a Short-Course Treatment with Synbiotics on Plasma p-Cresol Concentration in Kidney Transplant Recipients. 158
Experimental evidence and clinical implications of Warburg effect in the skeletal muscle of Fabry disease 150
Endocrine dysfunction in patients with Fabry disease 145
Alterations of functional connectivity of the motor cortex in Fabry disease: An RS-fMRI study 142
Corpus callosum involvement: a useful clue for differentiating Fabry Disease from Multiple Sclerosis 140
EC-MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side-effects. 136
Diagnostic, Predictive, Prognostic, and Therapeutic Molecular Biomarkers in Third Millennium: A Breakthrough in Gastric Cancer 132
6-tips diet: a simplified dietary approach in patients with chronic renal disease. A clinical randomized trial 131
Parapelvic cysts, a distinguishing feature of renal Fabry Disease. 131
Bowel obstruction and peritoneal carcinomatosis in the elderly. A systematic review 123
Current tissue molecular markers in colorectal cancer: A literature review 122
Renal sympathetic-nerve ablation for uncontrolled hypertension in a patient with single-kidney autosomal dominant polycystic kidney disease. 120
Effect of paricalcitol vs calcitriol on hemoglobin levels in chronic kidney disease patients: a randomized trial 120
Absence of infratentorial lesions in Fabry disease contributes to differential diagnosis with multiple sclerosis 119
The central vein sign helps in differentiating multiple sclerosis from its mimickers: lessons from Fabry disease 118
Plasma p-cresol lowering effect of sevelamer in non-dialysis CKD patients: evidence from a randomized controlled trial 118
A strange epigastric pain. 117
Hybrid positron emission tomography-magnetic resonance imaging for assessing different stages of cardiac impairment in patients with Anderson-Fabry disease: AFFINITY study group 117
Cerebrovascular and Brain Abnormalities In Autosomal-Dominant Polycystic Kidney Disease: Role Of 3d Time-of-Flight Magnetic Resonance Angiography 117
Striatonigral involvement in Fabry Disease: A quantitative and volumetric Magnetic Resonance Imaging study 117
Immunosuppression and multiple primary malignancies in kidney transplanted patients. A single-institute study 116
Pituitary function and morphology in Fabry disease. 116
Cardiopulmonary determinants of reduced exercise tolerance in Fabry disease 116
Default mode network modifications in Fabry disease: A resting-state fMRI study with structural correlations 115
Molecular Mechanisms of Renal Cellular Nephrotoxicity due to Radiocontrast Media 114
Atorvastatin improves the course of ischemic acute renal failure in aging rats 113
Effects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry disease. 113
Reduced intracranial volume in Fabry Disease: Evidence of abnormal neurodevelopment? 113
Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: A randomized trial 111
Endothelial-mediated coronary flow reserve in patients with Anderson-Fabry disease 110
Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy. 109
Genetic variants associated with gastrointestinal symptoms in Fabry disease. 109
Nutritional management in renal transplant recipients: A transplant team opportunity to improve graft survival 109
Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease 108
C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial 107
Cardiac performance during exercise in patients with Fabry's disease 106
RAAS Inhibitor Prescription and Hyperkalemia Event in Patients With Chronic Kidney Disease: A Single-Center Retrospective Study 105
Identifying Fabry patients in dialysis population: prevalence of GLA mutations by renal clinic screening, 1995–2019 105
ADPKD and metformin: from bench to bedside 105
Arginase inhibition slows the progression of renal failure in rats with renal ablation 104
Motor involvement in Fabry disease 103
Fatigue as hallmark of Fabry disease: role of bioenergetic alterations 102
Advanced CMR Techniques in Anderson-Fabry Disease: State of the Art 102
Prominent longitudinal strain reduction of left ventricular basal segments in treatment-naïve Anderson-Fabry disease patients 102
Prevalence of GLA gene mutations and polymorphisms in patients with multiple sclerosis: A cross-sectional study 102
Ketogenic diet in ADPKD patient 102
Optical Coherence Tomography Angiography Findings in Fabry Disease 101
Oral Sucrosomial® iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: a cost- minimization analysis. 101
Neuroimaging in Fabry disease: current knowledge and future directions 101
Familial polycystic kidneys with no genetic confirmation: Are we sure it is ADPKD? 99
Thyroid function in Fabry disease before and after enzyme replacement therapy. 99
Relationship between left ventricular diastolic function and myocardial sympathetic denervation measured by (123)I-meta-iodobenzylguanidine imaging in Anderson-Fabry disease 99
Redefining the Pulvinar Sign in Fabry Disease 99
An unusual case of tuberous sclerosis incidentally discovered in adulthood: case report and review of the literature 99
Early Biomarkers of Fabry Nephropathy: A Review of the Literature. 99
Early Cardiac Involvement Affects Left Ventricular Longitudinal Function in Females Carrying α-Galactosidase A Mutation: Role of Hybrid Positron Emission Tomography and Magnetic Resonance Imaging and Speckle-Tracking Echocardiography 98
Mutations in the GLA gene and LysoGb3: Is it really Anderson-Fabry disease? 98
Assessing brain involvement in Fabry disease with deep learning and the brain‐age paradigm 96
Effect of a low- versus moderate-protein diet on progression of CKD: follow-up of a randomized controlled trial. 96
Antiproteinuric effect of add-on paricalcitol in Fabry disease patients: a prospective observational study. 95
Atrial septum aneurysm: an unusual manifestation in ADPKD? 95
Molecular and clinical studies in five index cases with novel mutations in the GLA gene. 95
The effects of somatostatin analogues on liver volume and quality of life in polycystic liver disease: a meta-analysis of randomized controlled trials 95
Parapelvic Cysts: An Imaging Marker of Kidney Disease Potentially Leading to the Diagnosis of Treatable Rare Genetic Disorders? A Narrative Review of the Literature 94
Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter? 94
Metabolic effects of two low protein diets in chronic kidney disease stage 4-5--a randomized controlled trial. 94
Zaleplon improves sleep quality in maintenance hemodialysis patients. 94
Role of cardiac MRI in evaluating patients with Anderson-Fabry disease: assessing cardiac effects of long-term enzyme replacement therapy. 94
Terapia enzimatica sostitutiva nella malattia di Fabry: cosa abbiamo imparato dallo switch? 94
Insomnia in maintenance haemodialysis patients. 93
Home infusion program with enzyme replacement therapy for Fabry disease: The experience of a large Italian collaborative group 93
Multimodality imaging approach to Fabry cardiomyopathy: Any role for nuclear cardiology? 93
Randomized Controlled Trials on Renin Angiotensin Aldosterone System Inhibitors in Chronic Kidney Disease Stages 3-5: Are They Robust? A Fragility Index Analysis 92
sleep quality in renal transplant patients: a never investigated problem. 92
Ultra-deep dna methylation analysis of x-linked genes: Gla and ar as model genes [*De Riso G., Cuomo M co-primi autori] 92
Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement. 91
Prevention of contrast-induced nephropathy through a knowledge of its pathogenesis and risk factors 91
Fabry's disease: a comparison of the effectiveness of two different enzyme replacement therapies 91
The role of immunosuppressive therapy in aneurysmal degeneration of hemodialysis fistulas in renal transplant patients: Aneurysmatic arteriovenous fistula in transplant patients 91
Visceral Leishmaniasis in renal transplant recipients: is it still a challenge to the nephrologist? 90
The Choice of the Iodinated Radiographic Contrast Media to Prevent Contrast-Induced Nephropathy 90
Methylome Profiling in Fabry Disease in Clinical Practice: A Proof of Concept 90
Microstructural damage of the cortico-striatal and thalamo-cortical fibers in Fabry disease: a diffusion MRI tractometry study 89
Effects of Ha-Ras inhibition on ischemic acute renal failure in the rat 89
Effects of atorvastatin on renal function in patients with chronic renal failure. 89
Renal denervation in ADPKD: an exceptional case 89
Author response: Alterations of functional connectivity of the motor cortex in Fabry disease: An RS-fMRI study 89
Cardiovascular magnetic resonance native T1 mapping in Anderson-Fabry disease: a systematic review and meta-analysis 89
SWITCH TO AGALSIDASE ALFA AFTER THE SHORTAGE OF AGALSIDASE BETA IN FABRY DISEASE: A SYSTEMATIC REVIEW WITH METANALYSIS OF THE LITERATURE 88
Renal transplantation and sleep: a new life is not enough 87
Layer-specific longitudinal strain in Anderson–Fabry disease at diagnosis: A speckle tracking echocardiography analysis 87
Therapeutic advances in ADPKD: the future awaits 87
What indication, morbidity and mortality for central pancreatectomy in oncological surgery? A systematic review 86
Tolvaptan vs. somatostatin in the treatment of ADPKD: A review of the literature 86
Visceral Leishmaniasis in renal transplant recipients. Is it still a challange to the Nephrologist? 86
Stepwise shortening of agalsidase beta infusion duration in Fabry disease: Clinical experience with infusion rate escalation protocol 86
Totale 10.986
Salva come PNG Salva come JPEG
Categoria #
all - tutte 64.040
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 64.040
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021485 0 0 0 0 0 71 33 32 74 28 82 165
2021/20221.167 20 4 11 13 15 37 37 52 110 108 259 501
2022/20231.330 219 123 50 119 140 147 19 124 216 79 73 21
2023/20241.182 54 274 107 62 69 111 24 102 26 25 245 83
2024/20255.957 329 315 38 110 124 367 621 343 501 621 2.068 520
2025/20267.166 1.386 915 1.186 1.219 2.201 259 0 0 0 0 0 0
Totale 19.191